Inhibitors of fibroblast activation protein alpha

Details Inhibitors of fibroblast activation protein alpha Inhibitors of fibroblast activation protein alpha

2011-08-16

2011-08-16

Chung, Susannah (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S400000

Reexamination Certificate

active

07998997

ABSTRACT:
Disclosed are peptide-based compounds that include boronic acid or cyano functionality, which efficiently and selectively inhibit fibroblast activation protein alpha. Among other therapeutic utilities, the peptide-based compounds may be useful for the treatment of cancer.

REFERENCES:
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5106948 (1992-04-01), Kinder et al.
patent: 5159060 (1992-10-01), Kinder et al.
patent: 7399869 (2008-07-01), Cohen et al.
patent: 2005/0084490 (2005-04-01), Adams et al.
patent: WO-03/092605 (2003-11-01), None
patent: WO-2005/047297 (2005-05-01), None
patent: WO-2006/125227 (2006-11-01), None
Adams, S. et al., “PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism”,Cancer Research, 64(15):5471-5480 (Aug. 1, 2004).
Cheng, J. D. et al., “Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth”,Mol. Cancer Ther., 4(3):351-360 (Mar. 2005).
Coutts, S. J. et al., “Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2Position of Xaa-boroPro Dipeptides”,J. Med. Chem., 39(39):2087-2094 (American Chemical Society, Washington, DC, USA, May 10, 1996).
Hu, Y. et al., “Synthesis and structure-activity relationship ofN-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7”,Bioorg. Med. Chem. Lett., 15(19):4239-4242 (Pergamon, Elsevier Science, Great Britain, Oct. 1, 2005).
Kelly, T., “Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy”,Drug Resistance Updates, 8(1-2):51-58 (Churchill Livingstone, Edinburgh, Great Britain, Feb. 1, 2005).
Tran, T. et al., “Synthesis and structure—activity relationship ofN-acyl-Gly-,N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP”,Bioorg. Med. Chem. Lett., 17(5):1438-1442 (Pergamon, Elsevier Science, Great Britian, Feb. 14, 2007).
Villhauer, E. B. et al., “1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties”,J. Med. Chem., 46(13):2774-2789 (American Chemical Society, Washington DC, USA, Jan. 1, 2003).
Supplementary European Search Report dated Jun. 17, 2009.
International Search Report for PCT/US06/26258 mailed on Nov. 16, 2006.

Affiliated with

Also associated with

Rating

Inhibitors of fibroblast activation protein alpha does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of fibroblast activation protein alpha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of fibroblast activation protein alpha will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2789832